WINT windtreetx.com: Forward Price-to-Revenue Multiple

The projected P/S ratio on the GURU.Markets chart reflects a trend where the value has stabilized at , coinciding with the implementation of environmental waste recycling standards. Fundamentally, the growth of Windtree Therapeutics (WINT) relies on the efficacy of istaroxime in treating heart failure. The development strategy is based on seeking Asian licensees to replenish capital while completely eschewing mergers.

WINT (Windtree Therapeutics, Inc.) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

WINT (windtreetx.com): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price Windtree Therapeutics, Inc.|WINT - Average Forecast Price

- company stock capitalization data:

Market Valuation Windtree Therapeutics, Inc.|WINT - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share Windtree Therapeutics|WINT - Total Net Assets|Market Capitalization to Book Value Ratio windtreetx.com|WINT - Aggregate Asset Value

- debt and solvency information:

- net income and valuation multiples indicators:

WINT - Company Net Income|Future Profit Windtree Therapeutics|WINT - P/E Multiple|Projected Price to Earnings Windtree Therapeutics, Inc.|WINT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Windtree Therapeutics, Inc.|WINT - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Windtree Therapeutics|WINT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months windtreetx.com|WINT - Expected net earnings per share growth this year|Expected earnings per share growth for next year Windtree Therapeutics

- issuer revenue and sales details:

WINT - Company Sales|Projected Sales Volume Windtree Therapeutics, Inc.|WINT - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Windtree Therapeutics, Inc.

Summary company analysis:Windtree WINT

Product sample of Windtree Therapeutics, Inc.

This metric compares the current market value of Windtree Therapeutics (WINT) with projected sales volume to determine the extent of the premium paid for future cash flows. Amid liquidity shortages and continuous share issuance to cover expenses, the expected P/S trend allows for an assessment of whether capital dilution and clinical failure risks are justified by the current fundamental valuation of the business.

Competitors of Windtree Therapeutics

Forward P/S Multiple REGN (Regeneron)|iRhythm Technologies, Inc. (IRTC) - Market Cap to Future Revenue Ratio|LNTH: Forward Price-to-Revenue Multiple|Forward Price to Sales MLYS (Mineralys Corp)|HTFL (heartflow.com) - Forward Price-to-Revenue Multiple|KMTS: Price to Expected Revenue Ratio|ESPR (Esperion) - Forward P/S Multiple|AMRN: Forward Price to Sales|Forward P/S Multiple AVR|TNYA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio CVRx, Inc. CVRX|Forward Price to Sales MIST|Cardiol - Forward P/S Multiple|BEAT - Forward P/S Multiple|Tenax Therapeutics, Inc (TENX) - Price-to-Projected Revenue Ratio|Future Price to Revenue ADGM (Adagio Medical, Inc.)|BCDA (BioCardia, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio catheterprecision.com VTAK|Forward Price-to-Revenue Multiple ABIO (ARCA Biopharma)|Forward P/S Multiple acastipharma.com (ACST)|Aerovate - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio VERV (Verve Therapeutics Inc.)